Ondansetron, a 5HT3-antagonist, does not alter dynamic mechanical allodynia or spontaneous ongoing pain in peripheral neuropathy

Clinical Journal of Pain

Volumn 27, Issue 4, 2011, Pages 323-329

  Tuveson, Birgitta ^a,b   Leffler, Ann Sofie ^a,c   Hansson, Per ^a,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b DANDERYD HOSPITAL   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

brushing; dynamic mechanical allodynia; endogenous pain modulation; ondansetron; painful peripheral neuropathy

Indexed keywords

ONDANSETRON; PLACEBO;

ADULT; ALLODYNIA; ARTICLE; AUTONOMIC INNERVATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DYNAMIC MECHANICAL ALLODYNIA; FATIGUE; FEMALE; HEADACHE; HUMAN; MALE; NAUSEA; NEUROPATHIC PAIN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPONTANEOUS ONGOING PAIN; VISUAL ANALOG SCALE;

EID: 79954972055     PISSN: 07498047     EISSN: 15365409     Source Type: Journal    
DOI: 10.1097/AJP.0b013e31820215c5     Document Type: Article

References (31)

1. Fields H, Basbaum A. Central nervous system mechanisms of pain modulation. In: Wall P, Melzack R, eds. Central Nervous System Mechanisms of Pain Modulation. Edinburgh, TX: ChurchillLivingstone; 1999;309-329.
2. Zhuo M, Gebhart GF. Spinal serotonin receptors mediate descending facilitation of a nociceptive reflex from the nuclei reticularis gigantocellularis and gigantocellularis pars alpha in the rat. Brain Res. 1991;550:35-48.
3. Suzuki R, Rahman W, Hunt SP, et al. Descending facilitatory control of mechanically evoked responses is enhanced in deep dorsal horn neurones following peripheral nerve injury. Brain Res. 2004;1019:68-76. (Pubitemid 39078612)
4. Suzuki R, Rygh LJ, Dickenson AH. Bad news from the brain: descending 5-HT pathways that control spinal pain processing. Trends Pharmacol Sci. 2004;25:613-617. (Pubitemid 39458166)
5. Porreca F, Ossipov MH, Gebhart GF. Chronic pain and medullary descending facilitation. Trends Neurosci. 2002;25: 319-325. (Pubitemid 34667014)
6. Ossipov M, Lai J, Malan TJ, et al. Tonic descending facilitation as a mechanism of neuropathic pain. In: Hansson P, Fields H, Hill R, et al, eds. Tonic Descending Facilitation as a Mechanism of Neuropathic pain. Seattle: IASP press; 2001; 107-124.
7. Pertovaara A, Wei H, Hamalainen MM. Lidocaine in the rostroventromedial medulla and the periaqueductal gray attenuates allodynia in neuropathic rats. Neurosci Lett. 1996; 218:127-130. (Pubitemid 26380050)
8. Stewart W, Maxwell DJ. Morphological evidence for selective modulation by serotonin of a subpopulation of dorsal horn cells which possess the neurokinin-1 receptor. Eur J Neurosci. 2000;12:4583-4588. (Pubitemid 32037870)
9. Suzuki R, Dickenson A. Spinal and supraspinal contributions to central sensitization in peripheral neuropathy. Neurosignals. 2005;14:175-181. (Pubitemid 41417106)
10. McCleane GJ, Suzuki R, Dickenson AH. Does a single intravenous injection of the 5HT3 receptor antagonist ondan-setron have an analgesic effect in neuropathic pain? A double-blinded, placebo-controlled cross-over study. Anesth Analg. 2003;97:1474-1478. (Pubitemid 37310150)
11. Zeitz KP, Guy N, Malmberg AB, et al. The 5-HT3 subtype of serotonin receptor contributes to nociceptive processing via a novel subset of myelinated and unmyelinated nociceptors. J Neurosci. 2002;22:1010-1019. (Pubitemid 34141780)
12. Samuelsson M, Leffler AS, Hansson P. Dynamic mechanical allodynia: on the relationship between temporo-spatial stimu-lus parameters and evoked pain in patients with peripheral neuropathy. Pain. 2005;115:264-272. (Pubitemid 40725283)
13. Samuelsson M, Leffler AS, Johansson B, et al. On the repeatability of brush-evoked allodynia using a novel semi-quantitative method in patients with peripheral neuropathic pain. Pain. 2007;130:40-46. (Pubitemid 46843452)
14. Benedict CR, Arbogast R, Martin L, et al. Single-blind study of the effects of intravenous dolasetron mesylate versus ondansetron on electrocardiographic parameters in normal volunteers. J Cardiovasc Pharmacol. 1996;28:53-59. (Pubitemid 26190455)
15. Charbit B, Albaladejo P, Funck-Brentano C, et al. Prolonga-tion of QTc interval after postoperative nausea and vomiting treatment by droperidol or ondansetron. Anesthesiology. 2005; 102:1094-1100. (Pubitemid 40745825)
16. Olivier B, van Wijngaarden I, Soudijn W. 5-HT (3) receptor antagonists and anxiety: a preclinical and clinical review. Eur Neuropsychopharmacol. 2000;10:77-95. (Pubitemid 30120037)
17. Ferrari MD, Wilkinson M, Hirt D, et al. Efficacy of ICS 205-930, a novel 5-hydroxytryptamine3 (5-HT3) receptor antago-nist, in the prevention of migraine attacks: a complex answer to a simple question, ICS 205-930 Migraine Study Group. Pain. 1991;45:283-291.
18. Sellers EM, Toneatto T, Romach MK, et al. Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence. Alcohol Clin Exp Res. 1994;18:879-885. (Pubitemid 24264108)
19. Wolf H. Preclinical and clinical pharmacology of the 5-HT3 receptor antagonists. Scand J Rheumatol Suppl. 2000;113:37-45. (Pubitemid 32016435)
20. Blackwell CP, Harding SM. The clinical pharmacology of ondansetron. Eur J Cancer Clin Oncol. 1989;25(suppl 1):21-24; discussion 5-7.
21. Oatway MA, Chen Y, Weaver LC. The 5-HT3 receptor facilitates at-level mechanical allodynia following spinal cord injury. Pain. 2004;110:259-268. (Pubitemid 38953291)
22. Ossipov MH, Hong Sun T, Malan P Jr, et al. Mediation of spinal nerve injury induced tactile allodynia by descending facilitatory pathways in the dorsolateral funiculus in rats. Neurosci Lett. 2000;290:129-132. (Pubitemid 30628358)
23. Katz J, Finnerup NB, Dworkin RH. Clinical trial outcome in neuropathic pain: relationship to study characteristics. Neuro-logy. 2008;70:263-272. (Pubitemid 351156805)
24. Suzuki R, Rahman W, Rygh LJ, et al. Spinal-supraspinal serotonergic circuits regulating neuropathic pain and its treatment with gabapentin. Pain. 2005;117:292-303. (Pubitemid 41383525)
25. Marchi N, Guiso G, Caccia S, et al. Determinants of drug brain uptake in a rat model of seizure-associated malformations of cortical development. Neurobiol Dis. 2006; 24:429-442. (Pubitemid 44716673)
26. Simpson KH, Murphy P, Colthup PV, et al. Concentration of ondansetron in cerebrospinal fluid following oral dosing in volunteers. Psychopharmacology (Berl). 1992;109:497-498.
27. Hansson P. Difficulties in stratifying neuropathic pain by mechanisms. Eur J Pain. 2003;7:353-357. (Pubitemid 36858234)
28. Vierck CJ, Hansson PT, Yezierski RP. Clinical and pre-clinical pain assessment: are we measuring the same thing? Pain. 2008; 135:7-10.
29. Farber L, Haus U, Spath M, et al. Physiology and pathophysiology of the 5-HT3 receptor. Scand J Rheumatol Suppl. 2004;2-8.
30. Granot R, Day RO, Cohen ML, et al. Targeted pharma-cotherapy of evoked phenomena in neuropathic pain: a review of the current evidence. Pain Med. 2007;8:48-64. (Pubitemid 46128767)
31. Jorum E, Warncke T, Stubhaug A. Cold allodynia and hyperalgesia in neuropathic pain: the effect of N-methyl-D-aspartate (NMDA) receptor antagonist ketamine-a double-blind, cross-over comparison with alfentanil and placebo. Pain. 2003;101:229-235. (Pubitemid 36173763)